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Abstract
Background: Increasing the weekly frequency of hemodialysis sessions has positive effects, on the control of
several biological data of patients. However, knowledge about Daily HemoDialysis (DHD) practices is limited in
France. The aim of the present study was to describe the characteristics and treatment trajectories of all French
patients undergoing DHD.
Methods: All patients older than 18 years who started DHD between 2003 and 2012 in France were included and
followed until December 31, 2013. The patients’ demographic and clinical characteristics and treatment modalities
were extracted from the French Renal Epidemiological and Information Network (REIN) registry.
Results: During the inclusion period, 753 patients started DHD in France. Based on their median age (64 years),
patients were classified in two groups: “old” group (≥64 years) and “young” group (<64 years). Patients in the old
group had more comorbidities than in the young group: 48 % had diabetes (vs 29 % in the young group), 17 % an
active malignancy (vs 10 %) and 80 % ≥1 cardiovascular disease (vs 41 %). Concerning patients’ treatment trajectories,
496 (66 %) patients started with another dialysis before switching to DHD and 257 (34 %) directly with DHD. At the
end of the follow-up, 69 % of patients in the old group were dead (27.4 % in the young group) and kidney
transplantation was more frequent in the young group (30.4 % vs 0.5 %).
Conclusion: In France, DHD is proposed not only to young in rather good clinical conditions and waiting for
kidney transplantation, but also to old and frail patients with higher mortality.
Keywords: Daily hemodialysis, End stage renal disease, Patient profiles, Patients trajectories, REIN registry
Background
End Stage Renal Disease (ESRD) is a chronic progressive
disease and a major public health issue as indicated by
the dramatic increase in the number of patients treated
for ESRD worldwide and also in France [1, 2].
Hemodialysis (HD), three times per week, is the most
frequent renal replacement therapy (RRT) [3]. However, in
recent years, new HD regimens characterized by changes
in the weekly frequency [4–9], the session’s duration
[6–10] or the dialysis doses [8, 10–14] have been
assessed. The main aim of these modifications was to
reduce the side effects of thrice-weekly HD [4, 8, 15]
that are caused by the fluctuations in the level of
urea particles and their toxicity between HD sessions
[4, 6, 15–19], and also to improve the patients’ qual-
ity of life [4, 8, 10, 11, 20, 21] by decreasing the
number/duration of sessions and improving blood
purification [20–22].
Some studies have shown that increasing the weekly
frequency of dialysis sessions is the best approach to re-
produce the kidney physiological functional role, com-
pared to three times/week HD [5, 15, 18, 23]. For
instance, Daily HemoDialysis (DHD) consists of more
sessions per week (≥5), delivered either as shorter daily
sessions (1.5–3 h) [4, 8, 14, 15, 24] or as longer noctur-
nal sessions (≥5 h) [4, 8, 14, 15, 23, 24]. Some studies on
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DHD showed that the increased weekly frequency of dia-
lysis has positive effects on the control of blood pressure
[4, 8, 14, 19, 20, 23, 24], uremia [6, 10, 15, 19] and ven-
tricular hypertrophy [8, 14, 23–26] in patients with ESRD.
Several studies have also analyzed DHD effects on
survival [22, 23, 27–30]. Although most of them
found that survival was improved in patients under-
going DHD [22, 28–30], the study by Suri et al. re-
ported that the mortality rate was significantly higher
among patients treated with DHD than in those who
received conventional HD in in-center HD services
[27]. These authors used data from the International
Quotidian Dialysis Registry (IQDR) that includes data
from many different registries, such as the French Renal
Epidemiological and Information Network (REIN)
registry. As two-thirds of the data of this study were
extracted from the REIN registry, the patients were
mainly French, differently from other studies where
data, and thus patients, were mainly from the American
USRDS database [22, 28, 30]. Therefore, Suri and col-
leagues hypothesized that the French patients on DHD
were older and with more comorbid conditions than pa-
tients on conventional HD [27].
In France, patients undergoing DHD represented 1 %
of all prevalent cases in 2012 with regional disparities
ranging from 0 to 6 % [31]. However, and as mentioned
by Suri and colleagues, there are few information on
DHD practice and on the demographic and clinical char-
acteristics of the patients undergoing DHD in France.
Moreover, the reasons leading to choose DHD among
the different RRT options are not described. Neverthe-
less, literature data suggest that in France, DHD is pro-
posed both to young/active and old/frail patients.
Therefore, to better understand DHD practice in
France and in a view of future establishment of recom-
mendations for DHD by the nephrologist community,
the aim of this study was to determine the demographic
and clinical characteristics of patients on DHD. In
addition, the treatment trajectories before starting such
a treatment and also the different DHD protocols cur-
rently proposed in France will be studied.
Methods
Study population
The French REIN registry includes all patients with
ESRD undergoing RRT, dialysis or transplantation and
living in France. The registry was established in 2002
and since 2011 it covers the entire French territory. The
registry organization has been described in details else-
where [32].
This study was a retrospective analysis of data col-
lected in the REIN registry. For this work, we included
all patients aged 18 years and over who started DHD in
the French regions included in the REIN registry
between January 1, 2003 and December 31, 2012. We
excluded patients who initiated RRT in a French region
before the introduction of the registry (left truncated
data), those who received pre-emptive renal transplant-
ation and those undergoing DHD seven days per week.
Each patient was then followed until death or the study
end point (December 31, 2013).
Data collection
Patients’ and HD characteristics
To describe the patients’ characteristics at the first DHD,
two types of variables were collected: i) demographic
data: sex, age; ii) clinical data: smoking status (current/
former smoker and never smoked); Body Mass Index
(BMI); hemoglobin and albumin levels; comorbidities
and disabilities, such as cardiovascular diseases (coron-
ary artery disease, peripheral vascular disease, congestive
heart failure, arrhythmia, aneurism and cerebrovascular
disease), active malignancy, cirrhosis, respiratory disease,
physical or psychiatric disabilities and walking disability
(walks without help, needs partial assistance for transfers,
totally dependent for transfers). All clinical data were col-
lected at RRT initiation, then annually. Quantitative vari-
ables were grouped in clinically relevant classes.
DHD characteristics were described as: i) treatment
modality: conventional (hemodialysis) HD and DHD,
convective (hemodiafiltration, hemofiltration, biofiltration)
HD and DHD, peritoneal dialysis (PD); ii) treatment im-
plementation autonomy: autonomous (home and HD in
satellite units and non-assisted PD), and non-autonomous
dialysis (nurse-assisted PD, in-center HD; iii) number of
weekly sessions and duration of each session; iv) vascular
access (catheter, arterio-venous fistula, bypass); v) DHD
environment: in-center unit (hospital-based or medically
supervised unit); satellite unit (self-care or nurse-assisted)
and at home; vi) emergency start vs planned first dialysis
session. Treatment modalities were collected at RRT initi-
ation and every time the treatment modality was changed.
Treatment trajectories
To describe the patients’ treatment trajectories before
DHD initiation, several data included in the REIN regis-
try were used: i) date of the first RRT and treatment mo-
dalities; ii) dialysis modality changes before DHD; iii)
date of DHD initiation. Additionally, the clinical out-
come at the end of the follow-up period (31/12/2013)
was included: death; DHD; switch to <5 sessions/week
HD; PD; and kidney transplantation.
Statistical analysis
The patients’ characteristics at DHD initiation were
expressed as frequencies and percentages for categorical
variables, and as median and interquartile values (IQR)
for continuous variables. Demographic and clinical
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features as well as DHD modalities were described by
subgroups, based on the population’s median age, and
according to the treatment trajectories before DHD initi-
ation (patients directly on DHD and patients who had
other RRT before switching to DHD). The patients’
treatment trajectories after DHD initiation were also de-
scribed. The characteristics of different subgroups were
compared using a Khi-square test.
Patient survival and the access to renal transplantation
were assessed from dialysis initiation until death or De-
cember, 31 2013. Kaplan Meier survival curves have
been established. The Cox regression was applied to
evaluate the association between patients’ characteristics
and death in the total population and the access to renal
transplantation for patients less than 80 years. All vari-
ables associated with outcomes in unadjusted model
(p < 0.2) were included in an adjusted one. All vari-
ables presenting a p-value < 0.05 in final adjusted
model were considered as statistically significant.
Statistical analyses were performed with the Stata 11.1
software (College Station, TX).
Results
Between 2003 and 2012, 753 patients aged 18 years and
over started DHD in the 26 French regions contributing
to the REIN registry.
Demographic and clinical features
Table 1(a) and (b) summarize the demographic and clin-
ical characteristics of patients on DHD. Their mean age
at DHD initiation was 62 ± 17.7 years and 63.5 % of
them were male. Many patients had one or more comor-
bidities at DHD start: diabetes (38.6 % of all patients),
respiratory disease (15.4 %), active malignancy (13.4 %),
one or more cardiovascular diseases (60 %), or physical
or psychiatric disabilities (19.5 %).
Then, patients were divided in two groups based on
their median age at DHD initiation (64 years; Additional
file 1: Figure S1): young (<64 years; n = 376) and old
(≥64 years; n = 377) group. The patients’ mean age in the
young group was 47.2 ± 12 years and in the old group
was 76.6 ± 7 years. As expected, more patients in the old
group had comorbidities than in the young group
(Table 1(b)): diabetes (48.3 % vs 29 %, p < 0.001), active
malignancy (17.2 % vs 9.6 %, p = 0.002), one or more car-
diovascular disease (80 % vs 40 %, p < 0.001) and had
more frequently severe walking disabilities (12.7 % vs
6 %, p < 0.001).
Patients’ treatment trajectories before starting DHD
Then, patients were divided in two groups based on their
pre-DHD trajectory: patients who started RRT directly
with DHD (dDHD; n = 257) and patients who started with
other RRT before switching to DHD (sDHD; n = 496).
The percentage of patients aged ≥64 years was higher in
the dDHD than in the sDHD group (62 % vs 44 %) as well
as the proportion of patients with comorbidities or in bad
clinical conditions (Table 2). Specifically, albumin levels
were <30 g/dl in 33.5 % of patients in the dDHD group (vs
13.7 % in the sDHD group) and hemoglobin levels
<10 g/dl were detected in 47.9 % of patients in the dDHD
group (vs 23 % in the sDHD group). Moreover, more pa-
tients in the dDHD group had an active malignancy
(18.3 % vs 10.9 % in the sDHD group, p < 0.001) or serious
walking disabilities (16.3 % vs 5.8 % in the sDHD
group, p < 0.001).
Patient in the sDHD group switched to DHD after a me-
dian RRT duration of 2 years (IQR: 1–3.8). During this
period, 27 (5.4 %) changed at least once their dialysis
modality. Specifically, 19 patients switched from PD
to HD and eight patients from HD to PD. Only three
patients changed twice their treatment modality be-
fore switching to DHD. Conventional HD was the
pre-DHD treatment of choice among patients in the
sDHD group (82.7 %; n = 410), followed by PD (9.9 %;
n = 49) and convective HD (7.5 %; n = 37). Moreover,
non-autonomous dialysis, mainly in-center dialysis re-
quiring partial or total nurse assistance, was frequent
in the sDHD group (79 % of patients).
DHD regimens
At DHD initiation, 602 patients (80 %) had conventional
DHD (Table 3) with five sessions/week (24.4 %) or six ses-
sions/week (55.6 %). The others (20 %) had five sessions/
week (5.6 %) or six sessions/week (14.4 %) of convective
DHD. The session’s median duration was 3 h (IQR: 2–3).
Only seven patients had sessions longer than five hours.
Among the patients in the dDHD group, 146 (57 %) ini-
tiated DHD in emergency conditions compared to 140
(28 %) in the sDHD group. Patients in the dDHD group
had dialysis mainly in in-center HD services (92.6 %),
while patients in the sDHD group were dialyzed more
often in satellite units (29.6 %) or at home (8.1 %).
Clinical outcome at the end of the study
Patients underwent DHD for a median duration of
258 days (IQR: 52–487). At 12/31/2013, 363 patients were
dead (48.2 %), 141 patients (18.8 %) were still on DHD,
14.7 % underwent kidney transplantation, 17.3 % switched
to HD (<5 sessions per week) and 1.1 % to PD (Fig. 1).
Survival
The percentage of patients who died was higher in the
old group (69 %) than in the young group (27.4 %) and
dDHD patients died in higher proportion than sDHD
ones (60.3 % vs 42 %). The risk of dying at 2 years after
dialysis initiation was approximately of 12 % in sDHD
patients and of 50 % in dDHD ones (Additional file 1:
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Table 1 Demographical, biological (a) and clinical characteristics (b) at DHD initiation: whole population of patients with ESRD and
young and old group based on the median age (<64 vs ≥ 64 years)
(a) Whole population <64 years ≥64 years
(n = 753) (n = 376) (n = 377)
n (%) n (%) n (%) p
Gender 0.42
Male 478 (63.5) 244 (35) 234 (62)
Female 275 (36.5) 132 (65) 143 (38)
BMI (kg/m2)a 0.40
< 18.5 50 (6.6) 31 (8.2) 19 (5)
18.5–23 158 (21) 82 (21.8) 76 (20.2)
23–25 105 (13.9) 53 (14.2) 52 (13.8)
≥ 25 330 (43.8) 158 (42) 172 (45.6)
Missing 110 (14.6) 52 (13.8) 58 (15.4)
Albumin (g/dl) <0.001
< 30 154 (20.5) 54 (14.4) 100 (26.5)
≥ 30 490 (65.1) 265 (70.5) 225 (59.7)
Missing 109 (14.5) 57 (15.2) 52 (13.8)
Hemoglobin (g/dl) 0.26
< 10 237 (31.5) 118 (31.4) 119 (31.6)
10–12 295 (39.2) 137 (36.4) 158 (41.9)
> 12 172 (22.8) 92 (24.5) 80 (21.2)
Missing 49 (6.5) 29 (7.7) 20 (5.3)
Smoking status 0.02
Current/former smokers 305 (40.5) 166 (44) 139 (37)
Never smoker 366 (48.6) 180 (48) 186 (49.3)
Missing 82 (10.9) 30 (8) 52 (13.7)
(b) Whole population <64 years ≥64 years
(n = 753) (n = 376) (n = 377)
n (%) n (%) n (%) p
Diabetes <0.001
Yes 291 (38.7) 109 (29) 182 (48.3)
No 455 (60.4) 265 (70.5) 190 (50.4)
Missing 7 (0.9) 2 (0.5) 5 (1.3)
Active malignancyb 0.002
Yes 101 (13.4) 36 (9.6) 65 (17.2)
No 638 (84.7) 336 (89.4) 302 (80)
Missing 14 (1.9) 1 (1) 10 (2.8)
Respiratory Disease 0.01
Yes 116 (15.4) 45 (12) 71 (18.8)
No 620 (82.3) 325 (86.4) 295 (78.2)
Missing 17 (2.3) 6 (1.6) 11 (3)
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Figure S2 (a)). The mortality rate was high among old
dDHD patients (Additional file 1: Figure S2 (b)). As ex-
pected, all major comorbidities were associated with an
increased risk of death. In addition, there was a signifi-
cant increased risk of death for dDHD (HR = 2.91 95 %
CI: 2.36–3.6) and this association remained significant in
the adjusted model (Additional file 1: Table S1).
Renal transplantation
Patients older than 80 years (n = 102; 13.5 %) were ex-
cluded from the analysis of the access to renal transplant-
ation. During the follow-up, 37/205 dDHD (18 %) and
102/446 sDHD (23 %) patients were transplanted. dDHD
patients had a higher access to renal transplantation
(Additional file 1: Figure S3 (a)) in the unadjusted as
in the adjusted Cox model (HR = 2.03 95 % CI: 1.38–3.0;
Additional file 1: Table S2), and especially patients
<64 years (Additional file 1: Figure S3 (b)).
Discussion
This first study on all French patients who started
DHD between 2003 and 2012 shows the heterogeneity
of the demographic/clinical features and treatment
trajectories of this population. Our results indicate
that in France, DHD is proposed to old and frail pa-
tients with comorbidities who died in high proportion
and also to young patients with ESRD who are wait-
ing for kidney transplantation. Moreover, based on
their treatment trajectory, patients could be divided
in two groups: patients who started directly with
DHD (older and with many comorbidities) and pa-
tients who started with other RRT before switching to
DHD (younger, healthier and waiting for renal transplant-
ation). Finally, our analysis shows that DHD modalities in
France are various and depend on the individual patient’s
characteristics and pre-DHD treatment trajectories. The
heterogeneity of the profile of French patients undergoing
DHD could partially explain the contradicting results on
mortality in DHD reported by Suri and colleagues [27]
compared to other studies [22, 28–30].
The present work is the first study to include patients
with ESRD on DHD from all France regions over a long
period. To characterize this population, all major comor-
bidities and disabilities were taken into account. Add-
itionally, the REIN registry includes also data on the
treatment modalities as well as on the pre- and post-
Table 1 Demographical, biological (a) and clinical characteristics (b) at DHD initiation: whole population of patients with ESRD and
young and old group based on the median age (<64 vs ≥ 64 years) (Continued)
Hepatic disease 0.10
Yes 24 (3.2) 14 (3.7) 10 (2.6)
No 713 (94.7) 358 (95.3) 355 (94.2)
Missing 16 (2.1) 4 (1) 12 (3.2)
Cardiovascular Diseasec <0.001
0 297 (39.4) 222 (59) 75 (20)
1 160 (21.2) 69 (18.4) 91 (24)
2 125 (16.6) 36 (9.6) 89 (23.6)
> 2 171 (22.7) 49 (13) 122 (32.4)
Physical and/or Psychiatric Disabilities 0.10
Yes 147 (19.5) 73 (19.4) 74 (19.5)
No 567 (75.3) 290 (77) 277 (73.5)
Missing 39 (5.2) 13 (3.5) 26 (7)
Walking disability <0.001
Walks without help 502 (66.7) 299 (79.6) 203 (53.8)
Totally dependent for transfer 71 (9.4) 23 (6) 48 (12.7)
Needs assistance for transfer 92 (12.2) 19 (5) 73 (19.5)
Missing 88 (11.7) 35 (9.4) 53 (14)
Treatment modalityd <0.001
sDHD 496 (66) 278 (74) 218 (58)
dDHD 257 (34) 98 (26) 159 (42)
aBMI Body Mass Index
bActive malignancy: solid tumors or hematological malignancies; cCardiovascular Disease: myocardial infarction, arrhythmias, coronary insufficiency, heart failure,
arteritis of the lower limbs, cerebrovascular accident; dsDHD: patients who switched to DHD after other dialysis modalities; dDHD: patients who started directly
with DHD
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Table 2 Demographic, biological characteristics (a) and comorbidities (b) of patients based on their treatment trajectory (sDHD and
dDHD) at DHD initiation
(a) sDHD patients dDHD patientsd
(n = 496) (n = 257)
n (%) n (%) p
Gender 0.002
Male 330 (66.5) 148 (57.6)
Female 166 (33.5) 109 (42.4)
Age (years) <0.001
< 64 278 (56) 98 (38)
≥ 64 218 (44) 159 (62)
BMI (kg/m2)a <0.001
< 18.5 27 (5.4) 23 (8.9)
18.5–23 106 (21.4) 52 (20.2)
23–25 70 (14.1) 35 (13.6)
≥ 25 249 (50.2) 81 (31.5)
Missing 44 (8.9) 66 (25.7)
Albumin (g/dl) <0.001
< 30 68 (13.7) 86 (33.5)
≥ 30 374 (75.4) 116 (45.1)
Missing 54 (10.9) 55 (21.4)
Hemoglobin (g/dl) <0.001
< 10 114 (23) 123 (47.9)
10–12 226 (45.6) 69 (26.8)
> 12 135 (27.2) 37 (14.4)
Missing 21 (4.2) 28 (10.9)
Smoking status 0.003
Current/former smokers 220 (44.4) 85 (33.1)
Never smoker 232 (46.8) 134 (52.1)
Missing 44 (8.9) 38 (14.8)
(b) sDHD patients dDHD patientsd
(n = 496) (n = 257)
n (%) n (%) p
Diabetes 0.001
Yes 194 (39) 97 (37.7)
No 302 (61) 153 (59.5)
Missing 0 (0) 7 (2.7)
Active malignancyb <0.001
Yes 54 (10.9) 47 (18.3)
No 439 (88.5) 199 (77.4)
Missing 3 (0.6) 11 (4.3)
Respiratory Disease <0.001
Yes 81 (16.3) 35 (13.6)
No 412 (83.1) 208 (80.9)
Missing 3 (0.6) 14 (5.4)
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Table 2 Demographic, biological characteristics (a) and comorbidities (b) of patients based on their treatment trajectory (sDHD and
dDHD) at DHD initiation (Continued)
Hepatic disease <0.001
Yes 17 (3.4) 7 (2.7)
No 476 (96) 237 (92.2)
Missing 3 (0.6) 13 (5.1)
Cardiovascular Diseasec 0.25
0 206 (41.5) 91 (35.4)
1 96 (19.4) 64 (24.9)
2 82 (16.5) 43 (16.7)
> 2 112 (22.6) 59 (23)
Physical and/or Psychiatric Disabilities 0.001
Yes 89 (17.9) 58 (22.6)
No 391 (78.8) 176 (68.5)
Missing 16 (3.2) 23 (8.9)
Walking disability <0.001
Walks without help 373 (75.2) 129 (50.2)
Totally dependent for transfer 29 (5.8) 42 (16.3)
Needs assistance for transfer 55 (11.1) 37 (14.4)
Missing 39 (7.9) 49 (19.1)
aBMI Body Mass Index
bActive malignancy: solid tumors or hematological malignancies; cCardiovascular Disease: myocardial infarction, arrhythmias, coronary insufficiency, heart failure,
arteritis of the lower limbs, cerebrovascular accident; dsDHD: patients who switched to DHD after other dialysis modalities; dDHD: patients who started directly
with DHD
Table 3 DHD features
Whole population sDHD patients dDHD patientsb
(n = 753) (n = 496) (n = 257)
n (%) n (%) n (%) p
Autonomy 0.001
Autonomous 134 (18.8) 123 (24.5) 11 (4.3)
Non-autonomous 619 (82.2) 373 (75.2) 246 (95.7)
DHD modalitiesa 0.01
coDHD 602 (80) 383 (77.2) 219 (85.2)
cvDHD 151 (20) 113 (22.8) 38 (14.8)
Vascular access <0.001
Catheter 192 (25.5) 80 (16.1) 112 (43.6)
Arterio-venous fistula 378 (50.2) 326 (65.7) 52 (20.2)
Bypass 9 (1.2) 9 (1.8) 0 (0.0)
Other 26 (3.5) 6 (1.2) 20 (7.8)
DHD environment <0.001
At home 43 (5.8) 40 (8.1) 3 (1.2)
In-center 547 (72.6) 309 (62.3) 238 (92.6)
Satellite unit 163 (21.6) 147 (29.6) 16 (6.2)
acoDHD: conventional DHD, cvDHD convective DHD, bsDHD: patients who switched to DHD after other dialysis modalities; dDHD: patients who started directly
with DHD
Pladys et al. BMC Nephrology  (2016) 17:107 Page 7 of 10
DHD treatment switches. Therefore, and differently
from previous studies that only described the first RRT
modality and/or the length of the pre-DHD period
[16, 18, 22, 28, 33], we could analyze and describe all
the RRT modality changes before switching to DHD.
We extracted from the REIN registry information
on several comorbidities in order to precisely describe
the clinical status of patients on DHD. We found that
diabetes (38.6 % of all patients), cardiovascular diseases
(60 %) and other comorbidities (respiratory disease:
15.4 %, active malignancy: 13.4 %, walking disabilities:
21.6 %) are frequent among French patients undergoing
DHD. Previous studies focused mainly on cardiac
functions [8, 16, 25, 26] and less frequently on other
comorbidities [22, 27, 28, 30, 34], such as diabetes.
Indeed, cardiovascular complications are the leading cause
of mortality in patients with ESRD and the usual reason
for proposing DHD. Moreover, previous studies reported
lower percentages of patients on DHD with comorbidities:
between 19 and 32 % for diabetes [27, 28], and between
12 and 31 % for cardiovascular diseases [27, 34]. In
addition, our study indicates that French patients on DHD
are older (mean age: 62 years) than patients in previous
studies that assessed the effect of DHD on survival (mean
age: from 35.6 to 55.8 years) [27, 35]. These findings may
in part explain the higher mortality rate among patients
undergoing DHD compared with conventional HD
(HR = 1.3; p = 0.034) reported by Suri and colleagues [27]
and in disagreement with previous reports [22, 28–30, 33].
Indeed, our study highlights that a large proportion of
French patients on DHD are older and suffer from comor-
bidities, differently from the patients included in other
works. Inversely, they accessed more to renal transplant-
ation. Comparison with a similar population of patients
undergoing DHD is now essential to definitively conclude
on the survival benefit associated with DHD.
Patients in the dDHD group were more often dialyzed
via a catheter (43.6 %) than those in the sDHD group
(20.4 %) and started more frequently the treatment in
emergency conditions (57 % vs 28 %). Starting DHD in
an emergency situation often requires dialysis via a cath-
eter. This could explain why arterio-venous fistulae were
less common in our population (35.6 %) compared with
previous studies where vascular access by arterio-venous
fistula was used in 63 % [18; 27] to 89 % [35] of patients.
Moreover, 20 % of all our patients had albumin levels
<30 g/dl and 31 % hemoglobin levels <10 g/dl, suggest-
ing that our population is predisposed to malnutrition
[21, 23] and anemia [5, 21, 24]. The finding that 48 and
33.5 % of patients in the dDHD group had low
hemoglobin and albumin levels, respectively, indicates,
as reported in previous studies [9, 18, 21, 24, 36], that
patients started DHD as an emergency because of their
poor medical status which did not allow proposing thrice-
weekly HD with long sessions. Our results showed that
patients who started directly with DHD presented a higher
risk of mortality (HR = 2.44; 95 % CI: 1.91–3.11), but para-
doxically they had a better access to renal transplantation
(HR = 2.03; 95 % CI: 1.38–3.0). These results suggested
that profiles of DHD patients in France are heterogeneous:
dDHD is the first RRT of old and frail patients as well as
younger ones in better medical conditions.
The association between DHD and biological parame-
ters was impossible to measure in our study. Neverthe-
less, it has been reported that DHD improves the
control of hypertension [26]. DHD is also associated
with improved fluid and phosphorus management and
inflammatory factors [37]. No negative impacts of DHD
on residual renal function have been observed [38].
Arterio-venous fistula is the favorite vascular access for
DHD [18], and no statistically significant differences in
vascular access dysfunction or permanent failures among
Fig. 1 Patients’ treatment trajectories and outcome, by subgroups (sDHD: patients who switched to DHD after other dialysis modalities; dDHD:
patients who started directly with DHD). ¥PD: Peritoneal Dialysis; *HD < 5x: Hemodialysis <5sessions/week; ¶TX: transplantation
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DHD patients compared to conventional HD ones were
reported [39]. Finally, improvements of quality of life with
DHD have been largely studied [4, 8, 10, 11, 20, 21].
In the literature, the RRT trajectory of patients on
DHD has not been well described. In our study, patients
in the sDHD group had mainly thrice-weekly HD (81 %)
or PD (10 %) before switching to DHD. Only a third of
all our patients started directly with DHD. Among the
496 French patients who switched to DHD, 21 % had au-
tonomous dialysis requiring little nurse assistance and
therefore had fewer constraints than patients dialyzed in
outpatient units. Moreover, younger patients had often a
past history of autonomous dialysis before starting
DHD. Dialysis at home is associated with a better quality
of life and self-rehabilitation [6] and it is often proposed
to young patients in good clinical conditions [6, 33, 36].
Younger patients dialyzed at home have fewer comor-
bidities [28] and more access to renal transplantation
than older patients [22]. These observations could ex-
plain the association of DHD with improved patient sur-
vival. Indeed, these studies included patients in quite
good clinical conditions who expected to maintain their
social and professional lives, while being dialyzed every
day at home [4, 22, 28].
In France, the most frequently prescribed DHD regi-
men is HD (six 3 h-sessions per week). This protocol
has been extensively assessed and it is considered the
best choice [4–6, 24] to limit the large fluctuations of
body fluid volumes caused by thrice-weekly HD [4, 24].
Our results show that long nocturnal hemodialysis is
rarely used in France. Indeed, only 0.9 % of all patients
underwent five to six night sessions of more than five
hours/each per week. Nocturnal hemodialysis at home is
much developed in Canada and Australia to overcome
the geographical isolation of dialyzed patients [40]. Such
patients are remote-monitored during the night and
alerted if a problem that needs their intervention arises
[23, 36]. Home dialysis requires specific equipment and
organization. On the other hand, in France, there are
many dialysis facilities with satellite dialysis units [41] to
meet the patients’ demands in all regions and to avoid
patients’ isolation as observed in Canada and Australia.
The provision of care for patients in dialysis has an
important economic impact on the Health Insurance in
France as in the whole world. Costs associated with
medical supplies are more important for in-center DHD
[4, 42, 43] than out-center or home HD due to staff and
transport costs (reimbursed in France) [24, 44]. How-
ever, the development of low-flux machines at home
may reduce the costs of DHD.
The main limitation of our study is the lack in the REIN
registry of the medical reasons to explain the nephrologist’s
decision to start or to switch a patient to DHD, differently
from the USRDS registry where such reasons are
described. Moreover, data from REIN didn’t allow us to
evaluate the quality of life of patients included in the study.
Conclusions
Our analysis of the demographic/clinical features and
treatment trajectories of 753 French patients on DHD
shows that in France, DHD is administered to aged pa-
tients with multiple comorbidities and high mortality
and also to relatively younger patients on the waiting list
for renal transplantation. The heterogeneity of the pa-
tients’ profiles suggests that DHD indications in France
are various. Moreover, the data on the patients’ demo-
graphic and clinical characteristics and on their initial
RRT trajectories could be further used to analyze the as-
sociation between DHD and patient survival by taking
into account their comorbidities and access to renal
transplantation.
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